Niagen Bioscience (NAGE) Net Cash Flow Growth (1y) (2012 - 2026)
Niagen Bioscience (NAGE) Net Cash Flow Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.89 Bn | 468.10 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.12 Bn | 114.87 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | 53.46% |
| 10 | Niagen Bioscience | 257.33 Mn | 190.78 Mn | 19.98 Mn | -83.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -83.93% |
| Dec 31, 2025 | -95.73% |
| Sep 30, 2025 | -15.27% |
| Jun 30, 2025 | 1,407.81% |
| Mar 31, 2025 | 4,465.00% |
| Dec 31, 2024 | 2,121.38% |
| Sep 30, 2024 | 1,129.70% |
| Jun 30, 2024 | -90.20% |
| Mar 31, 2024 | -91.11% |
| Dec 31, 2023 | -92.31% |
| Sep 30, 2023 | 109.63% |
| Jun 30, 2023 | 183.27% |
| Mar 31, 2023 | 137.37% |
| Dec 31, 2022 | 247.02% |
| Sep 30, 2022 | 32.88% |
| Jun 30, 2022 | 33.69% |
| Mar 31, 2022 | -125.81% |
| Dec 31, 2021 | -500.57% |
| Sep 30, 2021 | -66.35% |
| Jun 30, 2021 | -211.95% |